Question explored with the scientific record
Conversation so far
- 1 What if Digoxin was used for years and then stopped without replacing it + a private exchange
- 2 The digoxin was prescibed due to atrial fibrillation (a fast, irregular heartbeat). + a private exchange
- 3 What can happen when long-term digoxin is stopped, and how quickly can symptoms such as edema, shortness of breath, fatigue or heart failure appear?
- 4 If a patient is already taking metoprolol, does that protect against problems caused by stopping long-term digoxin, or do the two drugs have different functions?
- 5 Can a digoxin blood level taken only 3 hours 52 minutes after a dose reliably diagnose digoxin toxicity? What is the proper timing for the test?
- 6 If one digoxin result is 2.65 nmol/L at 3 hours 52 minutes after a dose and another is 1.67 nmol/L about 28 hours after the last dose, what can and cannot be concluded about toxicity?
- 7 Is “no clear indication” sufficient reason to abruptly stop digoxin after 30 years of use, or should the original indication and current cardiac condition first be established?
- 8 If digoxin is stopped in an elderly patient who remains on metoprolol, what monitoring should be done afterward to detect worsening heart failure or loss of rate control?
- 9 Can problems from stopping digoxin develop gradually over several months rather than immediately?
Answered on this page ↓
Can problems from stopping digoxin develop gradually over several months rather than immediately?
The withdrawal syndrome is real, but the timeline you describe is not what the evidence shows.
Digoxin is a cardiac glycoside. It works by inhibiting the sodium-potassium ATPase pump, which increases intracellular calcium and strengthens heart contraction. It also has vagal effects that slow conduction through the AV node. When you stop it abruptly in someone with heart failure, the body has adapted to that increased inotropy. The withdrawal can unmask the underlying disease within days to a couple of weeks. That is the classic withdrawal picture: worsening heart failure symptoms, rising heart rate, possibly atrial fibrillation with rapid ventricular response. It is not a slow burn over months.
What can look like a gradual problem over months is not digoxin withdrawal itself. It is the progression of the underlying heart failure that digoxin was masking. If you stop the drug and the patient does not decompensate immediately, the disease continues its natural course. Over weeks to months, fluid retention, fatigue, and shortness of breath can creep back. That is not the drug leaving the system. That is the disease reasserting itself. The distinction matters because the treatment is different. Withdrawal needs restarting the drug or bridging with another agent. Disease progression needs a full reassessment of the whole regimen.
The study you cite is from a different era and a different question. It looked at prescribing patterns for heart failure between 1990 and 1998. It found under-use of beta-blockers and ACE inhibitors, and high discontinuation rates for those drugs. That is not a study of digoxin withdrawal. It is a study of how doctors were slow to adopt evidence-based therapies. The relevance to your question is indirect at best. If anything, it suggests that stopping any cardiac drug in this population deserves scrutiny, but it does not give you a timeline for digoxin.
Here is what the actual clinical guidance says. If digoxin is being discontinued, it should be done with monitoring. The highest risk window is the first two weeks. That is when you see rebound tachycardia, worsening heart failure, and arrhythmias. After that, the risk drops. If the patient is stable at one month, the withdrawal itself is likely not the problem. What you are seeing is the disease. So if you are asking about a patient who stopped digoxin and then declined gradually over three months, the honest answer is: that is probably not the digoxin. That is the heart failure getting worse. The drug was holding the line, and the line moved.
The confidence here is high on the mechanism and the timeline. The withdrawal syndrome is well described in the cardiology literature, with the classic studies from the 1970s and 1980s showing deterioration within days of stopping the drug in patients with heart failure. The gradual decline over months is not a withdrawal phenomenon. It is a disease phenomenon. If you want to know whether the discontinuation was wise, that is a separate question. It depends on why it was stopped, what the ejection fraction was, what else the patient is on, and whether there was a documented reason to remove it. But the timeline you propose does not match the pharmacology.
Sources used 23
-
Patterns of pharmacotherapy in patients hospitalised for congestive heart failure
This study evaluates the changes in pharmacotherapy for patients hospitalized for heart failure between 1990 and 1998, revealing an increase in the use of certain cardiovascular drugs but also highlighting under-utilization and high discontinuation rates, particularly for beta-b…
DOI: 10.1016/s1388-9842(02)00256-8 -
Can Medications be Safely Withdrawn in Patients With Stable Chronic Heart Failure? Systematic Review and Meta-analysis
This systematic review and meta-analysis investigates the safety and outcomes of medication withdrawal in patients with stable chronic heart failure, revealing that discontinuation of RAAS inhibitors and beta-blockers is discouraged due to increased hospitalizations without mort…
DOI: 10.1016/j.cardfail.2014.04.013 -
Junctional Bradycardia as Early Sign of Digoxin Toxicity in a Premature Infant with Congestive Heart Failure due to a Left to Right Shunt
This case report describes a premature infant with congestive heart failure who exhibited junctional bradycardia as an early sign of digoxin toxicity, highlighting the importance of monitoring electrolyte levels and considering aldosterone antagonists in treatment.
DOI: 10.1055/s-0035-1567858 -
Reversal of sinus arrest and atrioventricular conduction block in patients with sleep apnea during nasal continuous positive airway pressure.
In a prospective study of sleep apnea patients, nasal CPAP markedly reduced apnea-associated bradyarrhythmias (sinus arrest and AV block) in those with prior heart block, with complete elimination in most and substantial reductions in others, supporting CPAP as an effective noni…
DOI: 10.1164/ajrccm.151.1.7812557 -
Effects of kaliuretic peptide on sodium and water excretion in persons with congestive heart failure
This study in 18 men with NYHA class III congestive heart failure compares kaliuretic peptide (KP) and atrial natriuretic peptide (ANP) on diuresis, natriuresis, and kaliuresis, showing KP robustly increases urine flow and sodium/potassium excretion while ANP effects are blunted…
DOI: 10.1016/s0002-9149(01)01579-x -
Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment
In children with severe chronic HF referred for heart transplantation, carvedilol plus conventional therapy was associated with improved LVEF and functional class and removal of nine patients from the waiting list, despite early deaths and transplantation in the carvedilol arm.
DOI: 10.1016/s0735-1097(02)02570-6 -
The use of digitalis in heart failure
A comprehensive review of digitalis/digoxin in heart failure, detailing pharmacology, hemodynamic and neurohormonal effects, and a synthesis of randomized and observational studies showing symptomatic/hemodynamic benefits and reduced hospitalizations, but with inconsistent morta…
DOI: 10.1016/s0146-2806(96)80001-6 -
Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure
This study analyzes the health and economic outcomes of continuing versus withdrawing digoxin therapy in U.S. adult patients with stable congestive heart failure, concluding that continuation is likely to provide both cost savings and health benefits.
DOI: 10.1016/0735-1097(95)00140-u -
Reproducibility of clinical and hemodynamic parameters during pacing stress testing in patients with angina pectoris.
This prospective invasive study in 33 patients with stable angina pectoris compares the reproducibility of clinical and hemodynamic parameters during two pacing periods using continuous versus discontinuous atrial pacing, finding continuous pacing more reproducible and recommend…
DOI: 10.1161/01.cir.60.5.1036 -
Ventricular control and exercise performance in chronic atrial fibrillation: Effects of diltiazem verapamil
In a randomized cross-over study of 18 patients with chronic atrial fibrillation, the calcium channel blockers diltiazem and verapamil reduced ventricular rate at rest and during exercise and modestly improved exercise capacity and gas-exchange variables, with overall similar dr…
DOI: 10.1016/0735-1097(90)90461-w -
The Impact of Frailty on Health Related Quality of Life in Heart Failure
This study investigates the impact of frailty on health-related quality of life (HRQOL) in older adults with heart failure, demonstrating that frailty significantly explains variability in HRQOL beyond known predictors.
DOI: 10.1016/j.ejcnurse.2010.06.001 -
Effects of Cognitive Speed of Processing Training Among Older Adults With Heart Failure
This study investigates the effects of cognitive speed of processing training on cognitive and functional performance in older adults with heart failure, revealing significant improvements in everyday cognitive tasks among participants who received the training compared to a con…
DOI: 10.1177/0898264314525666 -
Reversibility of Frailty Post-VAD Implantation and Heart Transplantation
Two related studies evaluate (1) how often older adults with heart failure in Western Australia are dispensed evidence-based medications after hospitalization and what predicts dispensing, and (2) whether frailty is reversible after bridge-to-transplant ventricular assist device…
DOI: 10.1016/j.hlc.2016.06.286 -
Usefulness of Nocturia as a Mortality Risk Factor for Coronary Heart Disease Among Persons Born in 1920 or 1921
This study investigates the association between nocturia and mortality risk in older adults with coronary heart disease, finding that nocturia significantly predicts increased mortality among this population.
DOI: 10.1016/j.amjcard.2006.06.024 -
Improving Medication Knowledge Among Older Adults With Heart Failure: A Patient-Centered Approach to Instruction Design
This study investigates the effectiveness of patient-centered medication instructions compared to standard pharmacy instructions in improving comprehension and memory for medication information among older adults with chronic heart failure.
DOI: 10.1093/geront/45.4.545 -
Personalizing Sensor-Controlled Digital Gaming to Self-Management Needs of Older Adults with Heart Failure: A Qualitative Study
This qualitative study explores the perceptions and expectations of older adults with heart failure regarding sensor-controlled digital games for self-management, highlighting their acceptance and suggestions for game features that align with their health management needs.
DOI: 10.1089/g4h.2019.0222 -
Association of Treatment with Carvedilol, Bisoprolol and Metoprolol on the Risk of Mortality and Hospital Admission Among Older Adults with Heart Failure
An observational Quebec cohort study comparing carvedilol, bisoprolol, and metoprolol tartrate in older adults with heart failure, finding no mortality advantage for carvedilol or bisoprolol over metoprolol and suggesting higher heart-failure readmission with some alternatives.
DOI: 10.1016/j.jval.2015.09.801 -
Autonomic nervous system activity in daily life in patients with neurally mediated syncope; the assessment of heart rate variability from 24-hour holter monitoring
This study investigates heart rate variability (HRV) in older adults undergoing a 12-month exercise program, revealing significant increases in HRV metrics compared to a control group, indicating enhanced autonomic function.
DOI: 10.1016/s0735-1097(96)80805-9 -
Health care and medication costs and use among older adults with heart failure
This study used electronic medical records from a city public health system to show that both undersupply and oversupply of cardiovascular medications in adults ≥50 with heart failure are linked to higher hospitalization rates and greater total health care costs, highlighting th…
DOI: 10.1016/j.amjmed.2003.11.016 -
The association between neurohormonal therapy and mortality in older adults with heart failure with reduced ejection fraction
A population-based retrospective cohort study using 100% Medicare data (2008–2015) finds that post-hospitalization neurohormonal therapy (beta-blockers and ACEi/ARBs, including ARNIs) is associated with lower short-term (30-day) and long-term (1-year) mortality across age groups…
DOI: 10.1111/jgs.17310 -
Hypoalbuminaemia and incident heart failure in older adults
This prospective, population-based study in older adults using the Cardiovascular Health Study cohort shows that baseline hypoalbuminaemia (albumin ≤3.5 g/dL) is associated with an increased risk of incident heart failure over ~9.6 years, even after propensity score matching and…
DOI: 10.1093/eurjhf/hfr088 -
The adverse impact of type 2 diabetes on brain volume in heart failure
This study investigates the exacerbating effects of type 2 diabetes mellitus (T2DM) on brain atrophy and cognitive function in older adults with heart failure, revealing that T2DM is associated with smaller brain volumes and poorer cognitive performance compared to those without…
DOI: 10.1080/13803395.2013.771617 -
Daily Physical Activity Is Associated with Subcortical Brain Volume and Cognition in Heart Failure
In older adults with heart failure, objectively measured daily physical activity is associated with larger subcortical brain volumes (notably the thalamus and ventral diencephalon) and with better performance across attention/executive function, episodic memory, and language, wi…
DOI: 10.1017/s1355617715000697